Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Xuejun P Liu

Zeling Cai

Wei-Xing Shi

Jiejun Wu

Patrick Branigan

Bruce Randazzo

Shu Li

Ernesto Munoz

Julianty Angsana

Samuel DePrimo

Susan Flavin

A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

Safe and effective method of treating psoriasis with anti-IL-23 specific antibody

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Identification of antigenic peptides from multiple myeloma cells

Growing community of inventors

San Diego, CA, United States of America

Xuejun P Liu